

Speaker

Univ.-Prof. Dr., MBA Clemens Aigner
MedUni Wien, Vienna, Austria

OA Dr. PhD Michal Benej
Klinik Floridsdorf, Vienna, Austria

MD, PhD, FRCS Andrea (Mr.) Bille
Guy's Hospital, London, UK

OA Dr. Maximilian Hochmair
Klinik Floridsdorf, Vienna, Austria

OA Priv.-Doz. Dr. Thomas Klikovits
Klinik Floridsdorf, Vienna, Austria

Prim.^a Dr.ⁱⁿ Dagmar Krenbek
Klinik Floridsdorf, Vienna, Austria

Prof.ⁱⁿ Dr.ⁱⁿ Isabelle Schmitt-Optiz
University Hospital Zurich, Zurich, Switzerland

OA Dr. Andreas Rimner
University of Freiburg, Freiburg, Germany

Pr M.D., Ph.D. Arnaud Scherpereel
Hospital of the University (CHU) of Lille, Lille, France

OÄ Dr.ⁱⁿ Olivia Theisen-Lauk
Universitätsspital Zürich, Zurich, Switzerland

Prim. Priv.-Doz. Dr. Stefan Watzka
Klinik Floridsdorf, Vienna, Austria

Multimodal Mesothelioma Therapy – after MARS2

Registration-Page:
dv.tik.cc/MesotheliomaCongress2025



Organizer/Education Provider:



Registration/Congress Office:
MEDahead Gesellschaft für medizinische Information m.b.H.
Part of Futuro Publishing Group
Contactperson: Kerstin Schnecker
Tel.: 01/607 02 33-65, E-Mail: k.schnecker@medahead.at

SPONSORS (at time of printing):



Registration deadlines:
November 8th, 2025, for in-person attendance
November 12th, 2025, for online attendance

The link to the live stream will be sent to you in time.

In collaboration with (at time of printing):



Accreditation:
Medical CME points are being requested for this event.
Please provide your correct medical number when registering;
otherwise, points cannot be assigned.
This event is exclusively for medical professionals.

Participation is free of charge. Registration required.

Also via
WEB
Live-Stream

INVITATION
International Multidisciplinary
Symposia

Limited onsite-participant capacity

13th November 2025
9am–5pm

Klinik Floridsdorf
Bruenner Straße 68
1210 Vienna
Austria

Multimodal Mesothelioma
Therapy – after MARS2

Local Chairs: T. Klikovits • S. Watzka
Program Committee: M. Hochmair, T. Klikovits, I. Opitz, A. Rimner, S. Watzka

Welcome Note

Dear participants,

It is our great pleasure to invite you to our comprehensive one-day international mesothelioma symposium, bringing together leading experts from across Europe. This event offers a unique platform to discuss the latest advancements and challenges in the diagnosis and treatment of pleural mesothelioma — a complex and aggressive disease requiring coordinated, cross-specialty approaches.

During the symposium, we will explore state-of-the-art therapeutic strategies, with a particular focus on surgical interventions, systemic therapies, radiation and innovative multimodal treatments. Our international experts will share cutting-edge research, clinical experiences and perspectives that reflect the rapidly evolving landscape of mesothelioma care.



Thomas Klikovits



Stefan Watzka

By fostering collaboration between thoracic surgeons, oncologists, radiation-oncologists, pathologists, and researchers, this meeting aims to enhance our understanding and to optimize outcomes for patients with pleural mesothelioma. We are confident that the exchange of ideas and knowledge will inspire new approaches and strengthen international cooperation.

We look forward to welcoming you to Vienna for a day of engaging scientific exchange, professional networking and shared dedication to advancing the care of pleural mesothelioma.

Program

SESSION 1 (9 am–10:30 am) – CET: Histopathology and systemic treatment

“Histopathology and molecular profiling”
(D. Krenbek, Vienna, Austria)

“The new era of immunotherapy”
(A. Scherpereel, Lille, France)

“Future developments in the systemic treatment”
(M. Hochmair, Vienna, Austria)

BREAK (10:30 am–11:00 am) – CET

SESSION 2 (11 am–12:30 pm) – CET: The value of multimodality treatment including surgery

Keynote Lecture “Is mesothelioma surgery after MARS2 still appropriate?”,
(I. Opitz, Zurich, Switzerland)

“New concepts in radiation therapy of pleural mesothelioma”
(A. Rimner, Freiburg, Germany)

“Modern intracavitary treatment options”
(O. Theisen-Lauk, Zurich, Switzerland)

LUNCH BREAK (12:30 pm–1:30 pm) – CET

SESSION 3 (1:30 pm–3 pm) – CET: Individualized treatment

“Pro-Con discussion about routine pericardial and diaphragmatic resection in EPD”
(Pro: C. Aigner, Vienna, Austria; Con: A. Bille, London, UK)

“Therapeutic challenges in long-term survivors of pleural mesothelioma”
(S. Watzka, Vienna, Austria)

“How to select patients for optimal treatment strategies”
(T. Klikovits, Vienna, Austria)

BREAK (3:00 pm–3:30 pm) – CET

SESSION 4 (3:30 pm–5 pm) – CET: Staging and case discussion

“The new TNM-9 staging for PM”
(A. Bille, London, UK)

Presentation/Discussion of two clinical cases
(M. Benej, Vienna, Austria; O. Theisen-Lauk, Zurich, Switzerland)